Cancer (disambiguation)

TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma

Retrieved on: 
Wednesday, October 26, 2022
IND, Therapy, Company, Survival, Drug discovery, Clinical trial, Security (finance), U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Doctor of Philosophy, Nasdaq, Cancer, Real-time, Disease, PD-L1, Pancreatic tumor, Recurrence, Risk, CEO, Intellectual property, Coronavirus, FIH, Tumor microenvironment, Pancreatic cancer, Breast cancer, Glioblastoma, TTX, RNA, Annual report, Neoplasm, Gene expression, Patient, Technology, Someren-Eind, Breast, GLOBE, COVID-19, CRISPR, Transcoding, Investigational New Drug, Animal, Pancreas, CTO, Mouse, Pharmaceutical industry, Vaccine, Cancer (disambiguation)

BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma.

Key Points: 
  • BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma.
  • TransCode Therapeutics evaluated the bioactivity of its lead therapeutic candidate, TTX-MC138, applied as monotherapy, in a murine model of pancreatic adenocarcinoma.
  • In the study, mice bearing human pancreatic tumors implanted in their pancreas were treated once weekly for 10 weeks with TTX-MC138.
  • As with prior studies, we believe the data from this pancreatic cancer study further support advancement of TTX-MC138 into the clinic.

Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, August 11, 2022
Serum, PROC, Risk, ASCO, Metastasis, GLOBE, ORR, SEC, Clinical trial, Research, Annual report, Patient, Paclitaxel, Nivolumab, DABT, KOL, US, PFS, Toxic epidermal necrolysis, ...Continued, Terminology, Addition, Industry, Private Securities Litigation Reform Act, GAS6, BLA, Ovarian cancer, CMC, European Commission, Tectonic evolution of the Aravalli Mountains, Forward-looking statement, COVID-19, ITT, Kidney, Royal commission, Cancer, FDA, Population, Pancreas, Review, Company, Pancreatic cancer, Therapy, Lists of people executed in the United States, AXL, Progression-free survival, Pharmaceutical industry, Online gambling, Platinum, Cancer (disambiguation)

HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the Company), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported financial results for the second quarter ended June 30, 2022 and provided corporate updates.

Key Points: 
  • HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the Company), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported financial results for the second quarter ended June 30, 2022 and provided corporate updates.
  • We continued to achieve great progress for Aravive in the second quarter of 2022.
  • Our Phase 1b trial in pancreatic cancer has completed enrollment and updated results are anticipated later this year.
  • Revenues for the three months ended June 30, 2022 were $1.6 million, compared to $1.1 million for the three months ended March 31, 2022.

Aravive Reports First Quarter 2022 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, May 12, 2022
Royal commission, ITT, Serum, Risk, Company, Population, Private Securities Litigation Reform Act, Toxic epidermal necrolysis, Tectonic evolution of the Aravalli Mountains, European Commission, Progression-free survival, AXL, US FDA, Patient, Pharming, PROC, Review, US, ORR, COVID-19, BLA, Pancreas, Executive, Kidney, FDA, Cancer, CMC, PFS, Metastasis, GAS6, Forward-looking statement, Terminology, Ovarian cancer, DABT, Sale, Therapy, Pancreatic cancer, Clear cell renal cell carcinoma, SEC, LLC, Paclitaxel, Annual report, GLOBE, Pharmaceutical industry, Nasdaq, Cancer (disambiguation), Platinum

HOUSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the Company), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported financial results for the first quarter ended March 31, 2022 and provided corporate updates.

Key Points: 
  • HOUSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the Company), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported financial results for the first quarter ended March 31, 2022 and provided corporate updates.
  • The Company anticipates providing clinical updates on the Phase 2 study throughout 2022.
  • In March 2022, the Company announced new biomarker data from the Phase 1b portion of the trial in patients with ccRCC.
  • The company is on track to report additional updated results from the Phase 1b portion of the trial in the second quarter of 2022.